Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 4 results out of 4

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Buy Now

Data Insights

AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Data Insights

AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs...

Data Insights

AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs...

Data Insights

AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II drugs...